Scott Edil Pharmacia Limited

Scott-Edil Pharmacia Limited, established in 1996, is a prominent Indian pharmaceutical company committed to providing equitable and affordable healthcare. Incorporated as a public limited company on January 6, 2003, under the Corporate Identification Number (CIN) U24232CH2003PLC025699, the company is headquartered at Plot No. 28/6, Industrial Area, Phase-2, Chandigarh, India. The authorized share capital stands at ₹130 million, with a paid-up capital of ₹127.68 million. Scott-Edil Pharmacia Limited operates as a non-government company, focusing on the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. The company employs approximately 1,500 professionals across its operations. For more information, visit their official website at https://scott-edil.com/.

Scott-Edil Pharmacia Limited operates four state-of-the-art manufacturing plants, all compliant with WHO-GMP standards. Three of these facilities are located in Baddi, Himachal Pradesh, and one in Chandigarh, India. These plants are equipped with ultra-modern machinery and quality control laboratories, ensuring adherence to stringent quality standards. The manufacturing capabilities include injections (both dry and liquid forms), ophthalmic solutions, oral liquids, dry syrups, tablets, capsules, gels, hand sanitizers, dietary proteins, and food supplements.

The leadership team at Scott-Edil Pharmacia Limited comprises several key executives:

• Vaishali Aggarwal: Managing Director
• Sanjeev Kumar: Director
• Balram Krishan: Director
• Munish Kumar: Director
• Pushkin Sharma: Director
• Vipan Kumar: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

Scott-Edil Pharmacia Limited has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has undertaken efforts to obtain EU GMP certification for its facilities, aiming to enhance its market access in the European Union. While specific details regarding regulatory filings, approvals, and market access status in the United States, United Kingdom, Australia, and Japan are not publicly disclosed, the company's commitment to international quality standards suggests a proactive approach to compliance in these markets.

Scott-Edil Pharmacia Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to countries such as Russia, Ukraine, Georgia, Iraq, Afghanistan, Kazakhstan, Philippines, Vietnam, Yemen, South Sudan, Nigeria, Zimbabwe, and Sri Lanka. The pursuit of WHO prequalification for its facilities is a strategic move to facilitate access to these markets, as WHO prequalification is often a prerequisite for supplying medicines to various international organizations and countries.

Scott-Edil Pharmacia Limited demonstrates a diversified geographic strategy by exporting its products to a wide array of countries across different continents. This approach mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The ongoing efforts to obtain EU GMP certification and WHO prequalification reflect a strategic direction aimed at enhancing global market access and compliance with international standards.

Specific details regarding Scott-Edil Pharmacia Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's commitment to WHO-GMP standards and its pursuit of EU GMP certification suggest a focus on adhering to international quality standards, which may facilitate future interactions with regulatory bodies such as the FDA.

Scott-Edil Pharmacia Limited's manufacturing facilities are WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. The company is also in the process of obtaining EU GMP certification, aiming to meet the European Union's stringent manufacturing standards.

Scott-Edil Pharmacia Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company also possesses approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Scott-Edil Pharmacia Limited. The company's adherence to WHO-GMP standards and pursuit of EU GMP certification suggest a proactive approach to regulatory compliance.

Scott-Edil Pharmacia Limited operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share comparisons are not publicly disclosed, the company's extensive product portfolio, commitment to quality standards, and global export reach position it as a significant competitor in the industry.

Scott-Edil Pharmacia Limited's key differentiators include its extensive product portfolio of over 700 drug formulations across various therapeutic segments, adherence to international quality standards such as WHO-GMP and ISO 9001:2008 certifications, and a strong presence in both domestic and international markets.

Scott-Edil Pharmacia Limited's current strategic direction focuses on expanding its global footprint through exports, enhancing product offerings across multiple therapeutic categories, and obtaining international certifications to facilitate market access. The company's future outlook includes further diversification of its product portfolio and strengthening its position in emerging markets.

Scott-Edil Pharmacia Limited has a track record of consistent export volumes, with a total export value of $25.5 million USD and 1,018 shipments across 23 products in 10 therapeutic categories. The company's adherence to international quality standards and its proactive approach to obtaining certifications such as EU GMP and WHO prequalification indicate a reliable and consistent supplier.

Importers should verify the following certifications when considering products from Scott-Edil Pharmacia Limited:

• WHO-GMP Certification: Indicates compliance with the World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

• EU GMP Certification: Demonstrates adherence to the European Union's Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

• ISO 9001:2008 Certification: Reflects a commitment to quality management systems. Verification can be performed through the International Organization for Standardization (ISO) or by contacting the company.

When conducting due diligence on Scott-Edil Pharmacia Limited, consider the following steps:

• Verify Certifications: Confirm the validity of WHO-GMP, EU GMP, and ISO 9001:2008 certifications through the respective certifying bodies or the company.

• Assess Regulatory Compliance: Review the company's compliance with CDSCO and other relevant regulatory authorities.

• Evaluate Financial Health: Analyze financial statements and growth trends to assess the company's financial stability.

• Review Product Portfolio: Examine the range and quality of products offered to ensure they meet your requirements.

• Check Export Records: Assess the company's export history and consistency in delivery.

Red flags to watch for include expired or unverifiable certifications, inconsistent financial records, and a lack of transparency in operations. Recommended pre-order checks involve requesting recent inspection reports, customer testimonials, and samples of products for quality assessment.